This Week in Cardiology — Jul 27, 2026

Welcome to This Week in Cardiology. This week we're covering 6 notable papers spanning cardiac imaging and prevention, rhythm management and heart failure therapeutics, and clinical trial outcomes frameworks. Let's dive in.

In our first theme on advanced diagnostics and rhythm management, we look at new data on imaging and cardioversion waveforms. In Circulation, Verghese and colleagues evaluated the prognostic utility of incidental coronary artery calcium scores derived from nongated chest computed tomography scans using data from the Multi-Ethnic Study of Atherosclerosis [1]. Among 2472 participants who underwent paired same-day gated and nongated scans, nongated log-standardized calcium scores strongly correlated with gated scores. Compared with participants with zero calcium, those with moderate scores of 101 to 299 and severe scores of 300 or greater had a roughly doubled to fivefold higher risk of coronary heart disease, with area under the curve and C-statistics that were statistically similar between gated and nongated methods [1]. The authors highlight that these findings align with recent American College of Cardiology and American Heart Association dyslipidemia guidelines endorsing incidental nongated calcium scoring for risk stratification [1]. Moving to acute arrhythmia management, Nguyen and colleagues published a pragmatic randomized controlled trial in the Journal of the American Heart Association comparing rectilinear biphasic waveform and biphasic truncated exponential waveform shocks for direct current cardioversion of atrial fibrillation across three hospitals [2]. In 546 adult patients randomized 1:1, successful normal sinus rhythm at or beyond one minute after a first full-output shock occurred in 82.6 percent of the 200-joule rectilinear biphasic group and 84.4 percent of the 360-joule biphasic truncated exponential group, with no significant differences in repeat shock efficacy or safety events [2]. Clinicians can thus consider these waveforms interchangeable for atrial fibrillation cardioversion.

Next, we turn to heart failure therapeutics and the evolving landscape of cardiorenal metabolism. In the Journal of the American Heart Association, Naito and colleagues investigated the association between sodium-glucose cotransporter-2 inhibitor use at discharge and clinical outcomes in 5579 patients hospitalized for acute heart failure in the prospective West Tokyo Heart Failure 2 registry, with a specific focus on frailty [3]. Using propensity score-weighted models, discharge sodium-glucose cotransporter-2 inhibitor use was associated with a lower risk of the primary composite outcome of cardiac death or heart failure rehospitalization at 1 year, showing a hazard ratio of 0.76 [3]. Notably, this benefit was more pronounced in patients with baseline frailty, where the hazard ratio dropped to 0.59, whereas non-frail patients did not show a statistically significant reduction, and use was not associated with nutritional deterioration [3]. Complementing these registry findings, a comprehensive review by Zelniker and Braunwald in Nature Reviews Cardiology synthesizes the pleiotropic mechanisms underpinning the cardioprotective, nephroprotective, and metabolic benefits of empagliflozin and class-wide sodium-glucose cotransporter-2 inhibitors [4]. They emphasize that benefits are mediated by interconnected networks involving hemodynamics, endothelial restoration, improved mitochondrial bioenergetics, and attenuation of maladaptive remodeling, paving the way for optimized therapeutic sequencing in cardiovascular-kidney-metabolic care [4].

Finally, we examine two papers addressing critical gaps in clinical trial endpoints and stroke management. In the BMJ, Lun and colleagues review the complex landscape of breakthrough ischemic stroke in patients with atrial fibrillation who experience events despite appropriate direct oral anticoagulant therapy [5]. They propose the Atrial Fibrillation related BReakthrough Embolic Stroke criteria to standardize future trial populations and outline a systematic algorithm for investigation and management [5]. Addressing broader clinical trial design limitations, Ganesh and colleagues introduced a new framework in Circulation termed Major Adverse Cognitive Events, or MACE-Cog [6]. The authors point out that conventional cognitive assessments in cardiovascular diseases and stroke suffer from severe limitations, including sociocultural biases, high rates of non-completion, and missingness that introduces survivor bias [6]. The proposed MACE-Cog framework is an inclusive construct that captures multidimensional cognitive decline by integrating test performance failures due to behavioral factors, reported symptoms, activities of daily living impairment, new dementia diagnoses, and care home admissions without relying solely on traditional testing [6].

If you only have time for one paper this week, make it the evaluation of nongated coronary artery calcium scans by Verghese and colleagues in Circulation [1]. It provides robust, multi-ethnic validation that incidental calcium scoring from routine chest computed tomography can accurately stratify cardiovascular risk identically to dedicated gated scans, directly empowering clinicians to leverage millions of existing scans for preventative care in alignment with current guidelines [1].

Here are the key takeaways from this week in Cardiology. Incidental coronary artery calcium scoring on nongated chest computed tomography offers prognostic performance comparable to dedicated gated scans, providing a scalable pathway for atherosclerotic risk assessment [1]. Full-output rectilinear biphasic and biphasic truncated exponential waveform shocks demonstrate equivalent efficacy and safety for direct current cardioversion of atrial fibrillation [2]. Sodium-glucose cotransporter-2 inhibitor therapy at discharge is associated with reduced one-year mortality and heart failure readmission in acute heart failure patients, particularly among those with frailty, without causing nutritional harm [3]. The newly proposed Major Adverse Cognitive Events framework aims to eliminate attrition bias and standardize cognitive endpoints in cardiovascular and stroke clinical trials [6].

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.